Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 23, 2022 3:15pm

133 Views

Post# 35190235

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

"Never" huh? We'll see. Your hedge fund / MM employers has perpetually lived in "never - never land" with respect to ONCY - yet the ONCY has a "Phase 2 ready" immune molecule platform technology in pelareorep which aligns with Big Pharma's strategic needs to off-set their looming patent cliff challenges. But hey, you admitted to not owning shares in ONCY but your only here reasons here are to "gaslight" for you employer and try to recover from you own stupidity... so "ba-bye"

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario